Is Longeveron going out of business?

Longeveron Inc. (LGVN) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Longeveron Inc. (LGVN) scores 3 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 87.56% (YoY)

Five questions, kept separate

Survival - Critical

3-5 mo of estimated runway from 2026-06-30, based on $10.1M of cash and short-term investments against $33.4M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

45% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 87.56% (YoY)
• FCF margin: -2812.64%
• Debt / Equity: -0.91x (Net Cash)
• ROIC: -1943.57%
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.30y
• Revenue CAGR (3Y): -0.63%
• Revenue growth YoY: -9.18% (YoY)
• Return on Assets: -151.57%
• Cash Burn Deceleration: -221.33% QoQ improvement (Worsening)
• Revenue Quality: Quality concerns (DSO +14d, Rev +-9%)
• Price / Sales: 17.8x (see Valuation)

Read from filings through 2026-08-24.

Price as of 2026-09-07.